Viewing Study NCT02729051

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:56 PM
Ignite Modification Date: 2026-03-11 @ 7:40 AM
Study NCT ID: NCT02729051
Status: COMPLETED
Last Update Posted: 2019-07-15
First Post: 2016-03-31
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pulmonary Disease, Chronic Obstructive View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Chronic Obstructive Pulmonary Disease (COPD) View
None fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) View
None Umeclidinium bromide (UMEC) View
None Closed triple therapy View
None Placebo View
None Open triple therapy View
None fluticasone furoate/vilanterol (FF/VI) View